CG Oncology, Inc.

SecurityCGON / CG Oncology, Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership187,510 shares
Latest Disclosed Value $ 7,785,415
Barclays Plc reports 21.80% increase in ownership of CGON / CG Oncology, Inc.

On February 13, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 187,510 shares of CG Oncology, Inc. (US:CGON) valued at $7,785,415 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on March 31, 2026 disclosing 153,955 shares of CG Oncology, Inc.. This represents a change in shares of 21.80% during the quarter. The current value of the position is $10,517,436 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F CG ONCOLOGY COM 156944100 187,510 33,555 21.80 7,785 25.54 0.0019
2026-03-31 2025-09-30 13F/A-3 CG ONCOLOGY COM 156944100 153,955 -192,545 -55.57 6,201 -31.17 0.0013
2026-03-19 2025-09-30 13F/A-2 CG ONCOLOGY COM 156944100 90,520 -255,980 3,415 0.0009
2025-11-12 2025-09-30 13F CG ONCOLOGY COM 156944100 153,955 -192,545 6,201 0.0013
2026-02-27 2025-06-30 13F/A-2 CG ONCOLOGY COM 156944100 346,500 253,961 274.44 9,009 297.57 0.0021
2025-08-14 2025-06-30 13F/A-1 CG ONCOLOGY COM 156944100 346,500 253,961 9 0.0021
2025-08-13 2025-06-30 13F CG ONCOLOGY COM 156944100 346,500 253,961 9 0.0007
2026-03-17 2025-03-31 13F/A-1 CG ONCOLOGY COM 156944100 92,539 -8,718 -8.61 2,266 -21.97 0.0006
2025-05-15 2025-03-31 13F CG ONCOLOGY COM 156944100 92,539 -8,718 2 0.0006
2026-03-19 2024-12-31 13F/A-1 CG ONCOLOGY COM 156944100 101,257 10,737 11.86 2,904 -14.96 0.0008
2025-02-13 2024-12-31 13F CG ONCOLOGY COM 156944100 101,257 10,737 3 0.0008
2026-03-31 2024-09-30 13F/A-2 CG ONCOLOGY COM 156944100 90,520 69,523 331.11 3,415 415.86 0.0009
2024-11-19 2024-09-30 13F/A-1 CG ONCOLOGY COM 156944100 90,520 69,523 3 0.0009
2024-11-15 2024-09-30 13F CG ONCOLOGY COM 156944100 90,520 69,523 3 0.0003
2026-03-23 2024-06-30 13F/A-1 CG ONCOLOGY COM 156944100 20,997 4,644 28.40 663 -7.67 0.0002
2024-08-14 2024-06-30 13F CG ONCOLOGY COM 156944100 20,997 4,644 1 0.0002
2026-03-24 2024-03-31 13F/A-1 CG ONCOLOGY COM 156944100 16,353 16,353 718 0.0002
2024-05-15 2024-03-31 13F CG ONCOLOGY COM 156944100 16,353 16,353 1 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.